A Breath of Hope: New Inhaled Therapy Poised to Revolutionize Smoking Cessation

IRVINE, Calif. – February 10, 2026 – For the millions of smokers who want to quit, the path is notoriously difficult, paved with low success rates and high chances of relapse. Now, a potential game-changer has emerged from pharmaceutical and medtech company Qnovia, Inc., which today announced promising results from the first human study of its novel nicotine replacement therapy (NRT), RespiRx™.

The Phase 1 clinical trial data suggests that the handheld inhaler could be the first major NRT innovation in over two decades to effectively break the cycle of addiction. By delivering a cool mist of pharmaceutical-grade nicotine that mimics the rapid uptake of a combustible cigarette, RespiRx™ addresses the core reasons why traditional quit-smoking aids so often fail.

A Faster, Safer Alternative

The results from the 2025 clinical trial, which involved 25 healthy adult smokers, are compelling. In a randomized, three-way crossover study, researchers compared the effects of RespiRx™ against both a traditional cigarette and the Nicotrol Inhaler, a legacy NRT whose production was discontinued in 2023.

The findings showed that RespiRx™ delivers a cigarette-like speed of nicotine to the bloodstream. With just 10 puffs, participants reached peak blood nicotine levels (Cmax of 8.7 ng/mL) in approximately 7 minutes. This time to peak concentration (Tmax) is comparable to the roughly 6-minute Tmax of a combustible cigarette, a critical factor for satisfying the intense, immediate cravings that often lead to relapse. This performance significantly outpaces older NRTs like patches and gums, which deliver nicotine much more slowly.

Crucially, while the speed was comparable, the device delivered a lower overall plasma nicotine exposure than a cigarette, suggesting it can provide effective craving relief without excessive dosing. Participants also reported a meaningful reduction in their "urge-to-smoke" scores. From a safety perspective, the trial reported no serious adverse events, with only a moderate cough noted as a side effect.

"We are very encouraged by the results of the first-in-human FDA trial of RespiRx™," said Mario Danek, founder and CEO of Qnovia. "The findings show that our novel nicotine delivery method — via a cool mist, without any heating or combustion — matches the speed and habit-loop of smoking and vaping without the carcinogens."

Tackling a Global Health Crisis

The need for a more effective cessation tool is staggering. Smoking remains the world's leading cause of preventable death, responsible for an estimated 8 million deaths annually, according to the World Health Organization. While around 70% of the world's 1.2 billion smokers express a desire to quit, the reality is grim. Relapse rates hover between 60% and 90% within the first year, and many existing therapies fall short.

"Most current FDA-approved therapies were designed decades ago and fail to reflect the neurobiology, pharmacokinetics, and behavioral drivers of addiction," Danek added. These products, such as patches and lozenges, struggle to replicate the rapid nicotine spike and the sensory hand-to-mouth ritual that are central to the habit of smoking. This mismatch is a key reason for their limited real-world success.

Qnovia's RespiRx™ platform was engineered to bridge this gap. It is a cartridge-based, ultra-portable vibrating mesh nebulizer that delivers a controlled dose of nicotine directly to the lungs. This approach preserves the rapid onset and sensory cues that reinforce smoking behavior but does so without the smoke, tar, or thousands of carcinogens produced by burning tobacco.

The Path to Market and Competitive Landscape

Qnovia's announcement marks a significant milestone on a long regulatory and commercial journey. The company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) in October 2024, paving the way for the U.S.-based Phase 1 trial. With this positive data in hand, the company is poised to advance to later-stage trials, which will evaluate long-term efficacy and safety.

The company is well-capitalized for this journey, having raised $17 million in a Series A round in 2022, followed by a $16 million Series B round in late 2024. This investor confidence underscores the perceived potential of the RespiRx™ platform. Qnovia also plans to submit a marketing authorization application to the British Medicines and Healthcare products Regulatory Agency (MHRA) in 2026.

If approved, RespiRx™ would enter a complex and lucrative market. The global NRT market, dominated by giants like Haleon and Johnson & Johnson, was valued at nearly $3 billion in 2024 and is projected to grow steadily. However, the broader smoking cessation market, estimated at over $37 billion, also includes e-cigarettes, which have grown rapidly despite ongoing debate about their role in public health.

By positioning RespiRx™ as a medicinal product subject to rigorous pharmaceutical standards, Qnovia aims to differentiate it from consumer-grade e-cigarettes. This distinction is echoed by experts in the field.

Robert West, Chairman of Qnovia's Scientific Advisory Board and a world-renowned expert in smoking cessation, highlighted the long-standing challenge. "From the very early days of development of nicotine replacement therapy... the challenge was to find a way to give smokers the nicotine they crave in a way that eases their transition to becoming non-smokers," he commented. He noted that while traditional products were too slow, e-cigarettes have raised concerns about creating new addiction.

"Qnovia's nicotine device offers the prospect of a medicinal nicotine product that is effective at controlling cigarette cravings and easing the transition to smoking cessation for millions of smokers," West concluded.

The technology's potential extends beyond nicotine. Qnovia envisions its RespiRx™ platform as a versatile drug delivery system for treating other conditions, including asthma, COPD, and pain management, signaling a broader ambition to revolutionize inhaled therapeutics. As the company moves toward pivotal later-stage trials, millions of smokers and public health officials worldwide will be watching with bated breath.